Repare Therapeutics
Develops precision cancer therapies using synthetic lethality and CRISPR-based discovery platforms.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
* | $1.5m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 5530 % | 1635 % | (61 %) | 5 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (9 %) | - | (39732 %) | (1428 %) | (15 %) | (223 %) | (166 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (11 %) | - | (39568 %) | (1407 %) | (22 %) | (183 %) | (158 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 8 % | - | 29697 % | 1185 % | 90 % | 261 % | 217 % |
Source: Company filings or news article
Related Content
Repare Therapeutics is a clinical-stage precision oncology company headquartered in Montréal, Canada, with additional operations in Cambridge, Massachusetts. Founded in 2016, the company develops targeted cancer therapies using a synthetic lethality approach, aiming to exploit specific genetic vulnerabilities in tumor cells. Its proprietary SNIPRx platform enables genome-wide, CRISPR-enabled screening to identify synthetic lethal gene pairs. This platform supports the discovery of highly selective small-molecule inhibitors that target genomic instability, with a focus on DNA damage repair pathways.
The company’s lead candidates include camonsertib, an oral ATR inhibitor in Phase 1/2 trials for tumors with ATM or BRCA1/2 mutations; lunresertib, a PKMYT1 inhibitor in mid-stage development targeting cancers with CCNE1 amplification and certain tumor suppressor losses; RP-1664, a PLK4 inhibitor designed for tumors with TRIM37 alterations; and RP-3467, a Polθ ATPase inhibitor being tested both as monotherapy and in combination with the PARP inhibitor olaparib.
Repare has also expanded its capabilities through partnerships. In 2024, it entered a licensing agreement with DCx Biotherapeutics to apply its discovery platforms to the development of multi-modal antibody-drug conjugates. The company collaborates with leading institutions such as Debiopharm, Bristol-Myers Squibb, and the U.S. National Cancer Institute.
Keywords: Repare Therapeutics, synthetic lethality, SNIPRx, precision oncology, DNA damage repair, camonsertib, lunresertib, PKMYT1 inhibitor, ATR inhibitor, Montreal biotech, targeted cancer therapy, Nasdaq RPTX